Little Capricor hits the brakes on a stem cell trial for Duchenne MD following an allergic reaction
The penny stock player Capricor Therapeutics $CAPR has stumbled into another pitfall.
The biotech noted that it has voluntarily halted a clinical trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
